Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PHVS | CLUSTER | neutral | 4/10 | Three Pharvaris insiders (CMO, Chief Early Development, Director) sold a combined ~$2.19M in open-market transactions ov | May 5, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two Alkermes insiders, the EVP/CLO and EVP R&D/Chief Medical Officer, sold a combined $368K in open-market stock over fo | May 4, 2026 |
| TRDA | CLUSTER | bearish | 5/10 | Two top executives at Entrada Therapeutics sold a combined $629K in open-market sales over a 7-day window, with Presiden | May 4, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three NRIX insiders (CFO, CLO, CSO) sold a combined $231K in open-market sales, a trivial 0.014% of the company's $1.7B | May 4, 2026 |
| EBS | CLUSTER | neutral | 2/10 | Three directors of Emergent BioSolutions sold a total of approximately $385K in open-market shares over two days, repres | May 4, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Insider trading cluster at United Therapeutics shows minimal open-market sales totaling ~$1.92M against a $24.2B market | May 4, 2026 |
| CAPR | CLUSTER | neutral | 2/10 | Two insiders (CFO and EVP/General Counsel) exercised stock options and sold an aggregate of 50,000 shares at ~$31.70 eac | May 4, 2026 |
| ANIK | CLUSTER | mixed | 5/10 | Anika Therapeutics insiders (CEO and director) purchased $223K in open-market shares in the week following the Q1 2026 e | May 4, 2026 |
| SYRE | CLUSTER | neutral | 2/10 | CEO and CMO sold a combined $1.85M in open-market sales at ~$69.50, representing 0.027% of Spyre's $6.9B market cap. The | May 1, 2026 |
| PHVS | CLUSTER | neutral | 2/10 | Three Pharvaris insiders sold a total of $118K in stock over a one-week window, with the Chief Medical Officer accountin | May 1, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of ~$184K in open-market shares over a 7-day window, a | May 1, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | Three UTHR insiders (CEO, CFO, and a director) sold a total of ~$3.77M in open-market shares over a one-week period, rep | May 1, 2026 |
| PCSA | CLUSTER | bullish | 4/10 | Three C-suite executives at Processa Pharmaceuticals (CEO, CAO, CDO) purchased a combined ~$15.5K of stock on April 30, | May 1, 2026 |
| GEVO | CLUSTER | neutral | 2/10 | Two GEVO insiders, including the President & COO, sold a combined $103K in shares over a one-week window. The sales repr | Apr 30, 2026 |
| KNSA | CLUSTER | neutral | 3/10 | Kiniksa Pharmaceuticals CEO Sanj K. Patel and Director Barry D. Quart sold a combined $4.42M in open-market shares on Ap | Apr 30, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Two C-suite insiders at Nurix Therapeutics sold a combined $107K in open-market shares on April 30, 2026, following deri | Apr 30, 2026 |
| DYN | CLUSTER | neutral | 3/10 | Two Dyne Therapeutics directors sold a total of ~$1.15M in stock over a 7-day window, with Director Rhodes Jason P execu | Apr 30, 2026 |
| PCSA | CLUSTER | bullish | 6/10 | Nine insiders at Processa Pharmaceuticals, including the CEO, CFO, and multiple directors, made open-market purchases to | Apr 30, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three insiders at United Therapeutics (UTHR), including the CEO and CFO, sold a total of ~$3.48M in stock over a five-da | Apr 29, 2026 |
| WST | CLUSTER | neutral | 2/10 | Two WST insiders (Sr. VP HR and VP/CAO) sold a combined $1.13M in open-market shares on April 27, 2026, following the co | Apr 29, 2026 |
| BCAX | CLUSTER | neutral | 2/10 | Three top executives (CEO, CFO, CMO) sold a combined $692K in BCAX stock over the past week, but this represents only ~0 | Apr 28, 2026 |
| ABT | CLUSTER | neutral | 2/10 | Insider cluster at Abbott Laboratories shows two open-market purchases totaling $1.13M by the CFO and a director, plus r | Apr 28, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three insiders at United Therapeutics, including the CEO and CFO, sold a total of $3.48M in open-market shares over a we | Apr 28, 2026 |
| NTHI | CLUSTER | neutral | 2/10 | Two NEONC insiders, including the President, made small open-market purchases totaling ~$48K over the past week. The tot | Apr 28, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Insider cluster at United Therapeutics shows routine option exercises and small open-market sales by the CEO, CFO, and a | Apr 28, 2026 |
| PRLD | CLUSTER | bullish | 8/10 | Three major insiders (OrbiMed Advisors, Baker Bros. Advisors, and David P. Bonita) purchased a combined $15.51M of PRLD | Apr 28, 2026 |
| DYN | CLUSTER | neutral | 4/10 | Director Jason P. Rhodes sold $3.4M worth of DYN shares over a five-day window, with total insider selling of $3.4M repr | Apr 28, 2026 |
| DYN | CLUSTER | neutral | 2/10 | Two Dyne Therapeutics directors, Jason Rhodes and Dirk Kersten, sold a combined $423K in open-market stock over a 2-day | Apr 27, 2026 |
| HEPA | CLUSTER | mixed | 5/10 | Four Hepion insiders, including the Interim CEO and Executive Chairman, purchased $350K in shares at $0.04 on April 21, | Apr 27, 2026 |
| IRD | CLUSTER | neutral | 2/10 | Three insiders (CEO, CFO, CSO) sold small open-market stakes totaling ~$129K, or 0.035% of the company's $373M market ca | Apr 27, 2026 |